AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline

AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase 1 test as a potential treatment for B cell-mediated autoimmune disorders. The post AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline appeared first on MedCity News.

AbbVie snaps up CAR-T company in a deal worth $2.1 billion

Capstan Therapeutics approach has stirred excitement in the CAR-T field, which has stalled in recent years due to scientific and logistical hurdles.

AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo...

AbbVie to Buy Capstan for up to $2.1 Billion in Immunology Push

AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.

AbbVie Moves to Strengthen Autoimmune Portfolio with $2.1 Billion Capstan Therapeutics Acquisition

North Chicago-based biopharmaceutical giant AbbVie has announced a definitive agreement to acquire Capstan Therapeutics for...